Vlad Coric - Biohaven Pharmaceutical Chairman of the Board, Chief Executive Officer
| BHVN Stock | USD 45.23 0.36 0.79% |
Chairman
Mr. Vlad Coric, M.D., serves as Chief Executive Officer, Director of Biohaven Pharmaceutical Holding Company Limited. has served as our chief executive officer and as a director since October 2015. From January 2007 to September 2015, he served as a group director of global clinical research at BristolMyers Squibb Company, or BMS, focusing both in oncology global clinical research and neuroscience global clinical research. He was involved in multiple drug development programs, including marketed drugs such as Abilify, Opdivo, Yervoy, Daklinza and Sunvepra . Since July 2001, Dr. Coric has also continued to serve as an associate clinical professor of psychiatry at Yale School of Medicine. He previously served as the chief of the Yale Clinical Neuroscience Research Unit and the director of the Yale ObsessiveCompulsive Disorder Research Clinic. He has served as president of the Connecticut Psychiatric Society. Dr. Coric currently serves on the boards of directors of Vita Therapeutics and OLM School of Madison. Dr. Coric received his M.D. from Wake Forest University School of Medicine. He completed his internship at YaleNew Haven Hospital and residency training at the Yale Psychiatry Residency Training Program, where he also served as the programwide chief resident for the Yale Department of Psychiatry, and chief resident on the PTSD firm at the WestHaven Connecticut Veterans Administration Hospital since 2021.
| Age | 50 |
| Tenure | 3 years |
| Professional Marks | Ph.D |
| Address | 215 Church Street, New Haven, CT, United States, 06510 |
| Phone | 203 404 0410 |
| Web | https://www.biohaven.com |
Latest Insider Transactions
Coric was an honors scholar in neurobiology and physiology at the University of Connecticut where he received a B.S. degree. We believe that Dr. Coric’s operational experience with our Company gained from serving as our chief executive officer, as well as his extensive experience in the biopharmaceutical industry, qualifies him to serve as a member of our Board.Vlad Coric Latest Insider Activity
Tracking and analyzing the buying and selling activities of Vlad Coric against Biohaven Pharmaceutical stock is an integral part of due diligence when investing in Biohaven Pharmaceutical. Vlad Coric insider activity provides valuable insight into whether Biohaven Pharmaceutical is net buyers or sellers over its current business cycle. Note, Biohaven Pharmaceutical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Biohaven Pharmaceutical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Vlad Coric over six months ago Acquisition by Vlad Coric of 231 shares of Biohaven Pharmaceutical subject to Rule 16b-3 |
Biohaven Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of (1.1879) % which means that it has lost $1.1879 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.6545) %, meaning that it created substantial loss on money invested by shareholders. Biohaven Pharmaceutical's management efficiency ratios could be used to measure how well Biohaven Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.87. In addition to that, Return On Capital Employed is likely to drop to -1. At this time, Biohaven Pharmaceutical's Non Currrent Assets Other are very stable compared to the past year. As of the 26th of November 2024, Other Current Assets is likely to grow to about 63.7 M, while Total Assets are likely to drop about 347.2 M.Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| Yves Sabbagh | Inozyme Pharma | N/A | |
| Dr DPHIL | Kymera Therapeutics | 50 | |
| Douglas Treco | Inozyme Pharma | 66 | |
Management Performance
| Return On Equity | -2.65 | ||||
| Return On Asset | -1.19 |
Biohaven Pharmaceutical Leadership Team
Elected by the shareholders, the Biohaven Pharmaceutical's board of directors comprises two types of representatives: Biohaven Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biohaven. The board's role is to monitor Biohaven Pharmaceutical's management team and ensure that shareholders' interests are well served. Biohaven Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biohaven Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Warren JD, General Officer | ||
| John Childs, Independent Director | ||
| John Tilton, Chief Commercial Officer, Rare and Orphan Diseases | ||
| Rajesh Kumar, Senior Chain | ||
| Robert Hugin, Independent Director | ||
| Warren Volles, G Officer | ||
| Chris Barrett, Common Strategy | ||
| Michael Heffernan, Lead Independent Director | ||
| Vlad Coric, Chairman of the Board, Chief Executive Officer | ||
| Jennifer Porcelli, Vice Relations | ||
| Kishen Mehta, Director | ||
| Declan Doogan, Independent Chairman of the Board | ||
| Megan Dow, Vice Strategy | ||
| Steven Dworetzky, Senior Development | ||
| Dr DACVP, Chief Officer | ||
| Elyse Stock, Chief Medical Officer | ||
| Julia Gregory, Independent Director | ||
| Thomas Lynch, Chairman of the Board | ||
| Deb Young, Director Operations | ||
| Marianne MA, Senior Affairs | ||
| Gregory Bailey, Independent Director | ||
| Vladimir MD, Chairman CEO | ||
| George Clark, VP Officer | ||
| Matthew Buten, Chief Financial Officer | ||
| Gilbert Litalien, Senior Epidemiology | ||
| James Engelhart, Chief Financial Officer, Treasurer | ||
| Charles Conway, Chief Scientific Officer | ||
| Kimberly Gentile, Senior Vice President - Clinical Operations | ||
| Robert Berman, Lead - Special Projects and Medical Oversight | ||
| Clifford MS, Chief Officer | ||
| William Jones, Chief Commercial Officer, Migraine and Common Diseases |
Biohaven Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biohaven Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.65 | ||||
| Return On Asset | -1.19 | ||||
| Current Valuation | 4.26 B | ||||
| Shares Outstanding | 101.12 M | ||||
| Shares Owned By Insiders | 11.15 % | ||||
| Shares Owned By Institutions | 86.74 % | ||||
| Number Of Shares Shorted | 9.15 M | ||||
| Price To Earning | (4.25) X | ||||
| Price To Book | 14.59 X | ||||
| EBITDA | (429.14 M) |
Pair Trading with Biohaven Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biohaven Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biohaven Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biohaven Stock
| 0.72 | NKTX | Nkarta Inc | PairCorr |
| 0.65 | BACK | IMAC Holdings | PairCorr |
| 0.59 | VALN | Valneva SE ADR | PairCorr |
| 0.59 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.57 | CYRX | Cryoport | PairCorr |
The ability to find closely correlated positions to Biohaven Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biohaven Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biohaven Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biohaven Pharmaceutical Holding to buy it.
The correlation of Biohaven Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biohaven Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biohaven Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biohaven Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biohaven Pharmaceutical Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biohaven Pharmaceutical. If investors know Biohaven will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biohaven Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.37) | Return On Assets (1.19) | Return On Equity (2.65) |
The market value of Biohaven Pharmaceutical is measured differently than its book value, which is the value of Biohaven that is recorded on the company's balance sheet. Investors also form their own opinion of Biohaven Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biohaven Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biohaven Pharmaceutical's market value can be influenced by many factors that don't directly affect Biohaven Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biohaven Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biohaven Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biohaven Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.